- Home
- SGMT vs MIN Comparison
SGMT vs MIN Comparison
Compare SGMT & MIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- MIN
- Stock Information
- Founded
- SGMT 2006
- MIN 1988
- Country
- SGMT United States
- MIN United States
- Employees
- SGMT N/A
- MIN N/A
- Industry
- SGMT
- MIN Trusts Except Educational Religious and Charitable
- Sector
- SGMT
- MIN Finance
- Exchange
- SGMT Nasdaq
- MIN Nasdaq
- Market Cap
- SGMT 269.2M
- MIN 303.8M
- IPO Year
- SGMT 2023
- MIN N/A
- Fundamental
- Price
- SGMT $10.94
- MIN $2.65
- Analyst Decision
- SGMT Strong Buy
- MIN
- Analyst Count
- SGMT 6
- MIN 0
- Target Price
- SGMT $26.83
- MIN N/A
- AVG Volume (30 Days)
- SGMT 883.6K
- MIN 331.0K
- Earning Date
- SGMT 08-13-2025
- MIN 01-01-0001
- Dividend Yield
- SGMT N/A
- MIN 7.31%
- EPS Growth
- SGMT N/A
- MIN N/A
- EPS
- SGMT N/A
- MIN 0.08
- Revenue
- SGMT N/A
- MIN N/A
- Revenue This Year
- SGMT N/A
- MIN N/A
- Revenue Next Year
- SGMT N/A
- MIN N/A
- P/E Ratio
- SGMT N/A
- MIN $33.38
- Revenue Growth
- SGMT N/A
- MIN N/A
- 52 Week Low
- SGMT $1.73
- MIN $2.52
- 52 Week High
- SGMT $10.99
- MIN $2.88
- Technical
- Relative Strength Index (RSI)
- SGMT 68.84
- MIN 42.52
- Support Level
- SGMT $8.79
- MIN $2.63
- Resistance Level
- SGMT $10.99
- MIN $2.70
- Average True Range (ATR)
- SGMT 0.74
- MIN 0.02
- MACD
- SGMT -0.05
- MIN -0.00
- Stochastic Oscillator
- SGMT 82.20
- MIN 14.29
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.